Vutrisiran Met Primary and All Secondary Endpoints | ALNY Message Board Posts


Alnylam Pharmaceuticals

  ALNY website

ALNY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34975 of 34981  at  4/19/2021 2:22:49 PM  by

Steve_382


Vutrisiran Met Primary and All Secondary Endpoints

It's still a biotech, so nobody cares right now.
 
 
 
·15 min read

– At 9 Months, Vutrisiran Met Primary and All Secondary Endpoints, with Statistically Significant Improvements in Neuropathy, Quality of Life (QoL), and Gait Speed, Relative to Placebo –

– In Majority of Patients, Vutrisiran Showed Reversal of Polyneuropathy Manifestations with Improvements in Neuropathy and QoL, Relative to Baseline –

– Vutrisiran Also Met Key Exploratory Endpoints Including Measures of Nutritional Status, Overall Disability, and Cardiac Biomarker (NT-proBNP), Relative to Placebo –

– Vutrisiran Demonstrated Encouraging Safety and Tolerability Profile –

– In Addition, Alnylam Submits New Drug Application (NDA) with U.S. Food and Drug Administration (FDA) for Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR (hATTR) Amyloidosis in Adults –

– Company to Host Conference Call Today at 4:00 pm ET –

 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 0
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...